Core Viewpoint - HF Sinclair Corporation has announced the pricing terms for its cash tender offer to purchase all outstanding notes, with all other terms remaining unchanged as per the Offer to Purchase dated August 11, 2025 [1][2]. Tender Offer Details - The consideration for each series of notes accepted for purchase is determined by a fixed spread over the yield based on U.S. Treasury Securities [2]. - The tender offer will remain open until 5:00 p.m. New York City time on August 15, 2025, unless extended or terminated [6]. - Settlement for all validly tendered notes is expected on August 20, 2025 [7]. Notes Information - The tender offer includes: - 5.875% Senior Notes due 2026 with an aggregate principal amount of $153,585,000, a reference yield of 4.226%, and a tender offer consideration of $1,004.12 [3]. - 6.375% Senior Notes due 2027 with an aggregate principal amount of $249,875,000, a reference yield of 4.035%, and a tender offer consideration of $1,011.63 [3]. Company Overview - HF Sinclair Corporation is an independent energy company that produces and markets high-value light products, including gasoline, diesel fuel, and renewable diesel [10]. - The company operates refineries in multiple states and provides transportation, storage, and throughput services to the petroleum industry [10]. - HF Sinclair markets its refined products primarily in the Southwest U.S. and has a significant presence in the renewable diesel market [10].

Core Insights - Tonmya is the first FDA-approved therapy for fibromyalgia in over 15 years, representing a significant advancement for the treatment of this chronic pain condition affecting over 10 million adults in the U.S. [1][2] - The approval of Tonmya was based on two pivotal Phase 3 clinical trials that demonstrated its efficacy in significantly reducing fibromyalgia pain compared to placebo [2][10] - Tonmya is expected to be commercially available in the fourth quarter of 2025 [1][6] Company Overview - Tonix Pharmaceuticals Holding Corp. is a fully-integrated biotechnology company focused on developing treatments for central nervous system disorders, immunology, immuno-oncology, and infectious diseases [12][13] - The company has a proprietary formulation for Tonmya, which is a sublingual tablet designed for rapid absorption and reduced production of long half-life metabolites [9] Industry Context - Fibromyalgia is a chronic pain disorder that affects an estimated 10 million adults in the U.S., with approximately 80% being women. It is characterized by chronic widespread pain, fatigue, and sleep disturbances [8] - The chronic pain associated with fibromyalgia significantly disrupts patients' daily lives and is often inadequately managed due to a lack of effective treatment options [4][8]

Core Insights - Toll Brothers, Inc. announced the grand opening of seven model homes at The Station, a new luxury home community in Sunnyvale, California, featuring townhomes and condominiums near major tech employers [1][4] Group 1: Community Features - The Station offers two collections of luxury homes: Vantage at The Station and Terraces at The Station, with sizes ranging from 962 to over 2,387 square feet, accommodating up to 4 bedrooms and 3 baths [4] - Homes in The Station are priced from the upper $900,000s, indicating a premium market positioning [4] - The community includes amenities such as a clubhouse, children's playground, dog park, walking paths, and expansive lawns, enhancing the living experience [6] Group 2: Customer Experience - Toll Brothers provides a state-of-the-art Design Studio for customers to personalize their homes with a wide array of selections, supported by professional Design Consultants [5] - Move-in ready homes with Designer Appointed Features are available, allowing buyers to move in later this summer or fall [5] Group 3: Educational Opportunities - Residents have access to highly ranked local schools, including Ellis Elementary, Sunnyvale Middle School, and Fremont High School, as well as sought-after private schools [6] Group 4: Company Background - Toll Brothers is a Fortune 500 Company, recognized as the nation's leading builder of luxury homes, with operations in over 60 markets across 24 states [9] - The company has received multiple accolades, including being named one of Fortune magazine's World's Most Admired Companies for over 10 years [10]

Core Insights - 1847 Holdings LLC reported significant financial improvements in Q2 2025, with revenue increasing by 380.4% year-over-year to $12.8 million and gross profit rising by 461.8% to $6.7 million, resulting in a gross margin of 52.2% [2][3] - The company generated a net income from continuing operations of $23.7 million, an increase of $26.6 million compared to a loss in the prior year, largely driven by a gain on the change in fair value of warrant liabilities [5][6] - For the first half of 2025, revenue reached $22.9 million, marking an increase of $18.1 million from the previous year, and the company achieved positive cash flow from continuing operations of $973,606 [1][2] Financial Performance - Q2 2025 revenue was $12.8 million compared to $2.7 million in Q2 2024, reflecting a growth of $10.1 million [3] - Gross profit for Q2 2025 was $6.7 million, up from $1.2 million in Q2 2024, indicating a substantial increase [2][4] - Operating income improved to $2.5 million in Q2 2025 from a loss of $1.7 million in the same quarter of the previous year [2][4] Future Guidance - The company reaffirmed its 2025 guidance, projecting net income of approximately $1.3 million on revenue exceeding $45 million, and anticipates 2026 net income of around $5.0 million on revenue surpassing $60 million [1][2] - 1847 Holdings is transitioning its shares to the OTCID Basic Market following a delisting from NYSE American, with plans to reapply for a national exchange listing in the future [2][7] Strategic Focus - The company focuses on acquiring undervalued businesses, enhancing their operations, and monetizing them for higher valuations, which aligns with its investment thesis of capitalizing on market inefficiencies [7]

GRAND RAPIDS, Mich., Aug. 15, 2025 (GLOBE NEWSWIRE) -- Independent Bank Corporation (NASDAQ: IBCP), the holding company of Independent Bank, announced with great sadness that Michael M. Magee, Jr., current Board member and past Chairman (2013-2024) of the Board of Directors for Independent Bank Corporation and Independent Bank, passed away on August 3, 2025. “The entire Independent Bank community is deeply saddened by Mike’s passing,” said Independent Bank President and CEO, Brad Kessel. “Mike served Indepe ...

Core Insights - LiTime's 12V 100Ah Smart ComFlex Battery has achieved full compatibility with Victron Energy's energy management systems, providing an intelligent and affordable energy solution for RV and marine users [1][5][9] - The integration allows for cell-level monitoring and real-time charge optimization without the need for additional accessories, significantly reducing system integration costs [9][12] - LiTime plans to expand its product line with new battery models and enhance compatibility with more third-party platforms, aiming to create a comprehensive intelligent energy ecosystem [14][15][17] Company Overview - LiTime specializes in lithium iron phosphate (LiFePO₄) battery technology and has 16 years of experience in the energy storage industry, focusing on intelligent and flexible energy solutions [4][18] - The company has a global customer support network and has received over 380 product certifications worldwide, emphasizing its commitment to quality and innovation [18] Industry Context - The RV and marine markets have historically faced challenges in selecting batteries that integrate well with energy management systems, often leading to a trade-off between cost and functionality [7][8] - There is a growing demand for intelligent and affordable energy management solutions that can enhance user experience and operational efficiency [8][9] Product Features - The LiTime 12V 100Ah Smart ComFlex Battery supports up to 16 units in parallel and provides real-time reporting of critical data to the Victron system, optimizing charge strategies and improving energy efficiency [12] - The battery features plug-and-play installation with a built-in smart BMS and supports over-the-air firmware updates, ensuring continuous improvement and compatibility with additional systems [12][15] Future Developments - LiTime is set to launch its 48V 100Ah Smart ComFlex Battery in Q3 2025 and a 24V 100Ah model in Q4 2025, with plans for further market expansion [14][15] - The company aims to integrate AI-powered predictive analysis and edge-computing adaptive control to enhance energy management experiences for users [17]

KING in Seattle is recognized for Overall Excellence in Large Market Television, marking the fourth consecutive year a TEGNA station receives the honorTYSONS, Va., Aug. 15, 2025 (GLOBE NEWSWIRE) -- TEGNA Inc. (NYSE: TGNA) today announced four of its stations have received 2025 National Edward R. Murrow Awards for excellence in broadcast journalism. KING in Seattle was recognized for Overall Excellence, Large Market Television, marking the fourth consecutive year a TEGNA station has received this honor. The ...

The Shareholder Meeting of Fly Play hf. (the “Company”) was held on Friday 15 August 2025 at 16:00 (GMT) at the Company’s offices at Suðurlandsbraut 14, 108 Reykjavík. Attached are the proposals of the Board of Directors that were approved at the shareholders meeting. Attachment Fly Play - Notice post Shareholders Meeting ...

TORONTO, Canada, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Canadian General Investments, Limited (TSX:CGI) (LSE: CGI) (the Company), announces that it has submitted its 2025 Interim Report, which includes the Management Report of Fund Performance and unaudited Financial Statements, to applicable Canadian securities regulators and to the National Storage Mechanism (https://data.fca.org.uk/#/nsm/nationalstoragemechanism). A PDF version of the document is also available at www.canadiangeneralinvestments.ca and at www. ...

Core Insights - Bioxytran, Inc. has achieved a significant scientific milestone with the publication of a book by Prof. Avraham Mayevsky, focusing on oxygen regulation and mitochondrial health, which could transform treatments for stroke, Alzheimer's, and other critical conditions [1][2]. Group 1: Scientific Advancements - The research highlights the inadequacy of current medical practices that rely on peripheral oxygen measurements, which can overlook critical issues within vital organs, such as in stroke patients who may have "100% oxygen saturation" while their brain is deprived of oxygen [2]. - Prof. Mayevsky's work emphasizes the importance of transitioning to tissue-specific oxygenation monitoring, which can lead to improved outcomes in clinical settings, particularly in the operating room [2]. Group 2: Clinical Applications - Bioxytran is integrating insights from this research into its upcoming BXT-25 clinical trials, which aim to demonstrate that targeted oxygen delivery can effectively rescue damaged tissues and potentially change treatment paradigms [3]. - The technology developed by Bioxytran is expected to serve as a biomarker for advancing clinical trials of BXT-25, providing a powerful method to measure brain oxygen consumption during strokes [3]. Group 3: Future Potential - Avraham Mayevsky stated that Bioxytran is positioned to lead the oxygen therapeutics revolution, with the principles outlined in his book potentially accelerating treatments for stroke, chronic wounds, and Alzheimer's by restoring oxygen delivery [4]. - Bioxytran is focused on developing complex carbohydrate-based therapeutics to address unmet medical needs across various platforms, including virology, cancer metastasis, and oxygen transport [4].